Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine von Blum, William, Garzon, Ramiro, Klisovic, Rebecca B, Schwind, Sebastian, Walker, Alison, Geyer, Susan, Liu, Shujun, Havelange, Violaine, Becker, Heiko, Schaaf, Larry, Mickle, Jon, Devine, Hollie, Kefauver, Cheryl, Devine, Steven M, Chan, Kenneth K, Heerema, Nyla A, Bloomfield, Clara D, Grever, Michael R, Byrd, John C, Villalona-Calero, Miguel, Croce, Carlo M, Marcucci, Guido

Volltext

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia von Blum, William, Schwind, Sebastian, Tarighat, Somayeh S., Geyer, Susan, Eisfeld, Ann-Kathrin, Whitman, Susan, Walker, Alison, Klisovic, Rebecca, Byrd, John C., Santhanam, Ramasamy, Wang, Hongyan, Curfman, John P., Devine, Steven M., Jacob, Samson, Garr, Celia, Kefauver, Cheryl, Perrotti, Danilo, Chan, Kenneth K., Bloomfield, Clara D., Caligiuri, Michael A., Grever, Michael R., Garzon, Ramiro, Marcucci, Guido

Volltext

Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia von BLUM, William, KLISOVIC, Rebecca B, PLASS, Christoph, DEVINE, Steven M, HEEREMA, Nyla A, MURGO, Anthony, CHAN, Kenneth K, GREVER, Michael R, BYRD, John C, MARCUCCI, Guido, HACKANSON, Bjoern, ZHONGFA LIU, SHUJUN LIU, DEVINE, Hollie, VUKOSAVLJEVIC, Tamara, HUYNH, Lenguyen, LOZANSKI, Gerard, KEFAUVER, Cheryl

Volltext

Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia von ANDRITSOS, Leslie A, JOHNSON, Amy J, WANG, Da-Sheng, KNIGHT, Robert D, RUPPERT, Amy S, LEHMAN, Amy, JARJOURA, David, CHEN, Ching-Shih, BYRD, John C, LOZANSKI, Gerard, BLUM, William, KEFAUVER, Cheryl, AWAN, Farrukh, SMITH, Lisa L, LAPALOMBELLA, Rosa, MAY, Sarah E, RAYMOND, Chelsey A

Volltext

Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias von William Blum, Rebecca B. Klisovic, Heiko Becker, Xiaoxia Yang, Darlene M. Rozewski, Mitch A. Phelps, Ramiro Garzon, Alison Walker, Jason C. Chandler, Susan P. Whitman, John Curfman, Shujun Liu, Larry Schaaf, Jon Mickle, Cheryl Kefauver, Steven M. Devine, Michael R. Grever, Guido Marcucci, and, John C. Byrd

Volltext

Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity von MARCUCCI, Guide, STOCK, Wendy, MORAN, Mollie, MAHARRY, Kati, NOVICK, Steven, BLOOMFIELD, Clara D, ZWIEBEL, James A, LARSON, Richard A, GREVER, Michael R, CHAN, Kenneth K, BYRD, John C, GUOWEI DAI, KLISOVIC, Rebecca B, SHUJUN LIU, KLISOVIC, Marko I, BLUM, William, KEFAUVER, Cheryl, SHER, Dorie A, GREEN, Margaret

Volltext

A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma von GRIGNOL, Valerie P, OLENCKI, Thomas, CARSON, William E, RELEKAR, Kiran, TAYLOR, Cynthia, KIBLER, Amanda, KEFAUVER, Cheryl, LAI WEI, WALKER, Michael J, CHEN, Helen X, KENDRA, Kari

Volltext

Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias von BLUM, William, PHELPS, Mitch A, JOHNSON, Amy, SCHAAF, Larry J, BYRD, John C, MARCUCCI, Guido, GREVER, Michael R, KLISOVIC, Rebecca B, ROZEWSKI, Darlene M, WENJUN NI, ALBANESE, Katie A, ROVIN, Brad, KEFAUVER, Cheryl, DEVINE, Steven M, LUCAS, David M

Volltext

A Dose Escalation and Pharmacodynamic Study of Triapine and Radiation in Patients With Locally Advanced Pancreas Cancer von Martin, Ludmila Katherine, MD, Grecula, John, MD, Jia, Guang, MD, Wei, Lai, PhD, Yang, Xiangyu, MD, Otterson, Gregory A., MD, Wu, Xin, MD, Harper, Erica, BS, Kefauver, Cheryl, BS, Zhou, Bing-Sen, MD, Yen, Yun, MD, Bloomston, Mark, MD, Knopp, Michael, MD, Ivy, S. Percy, MD, Grever, Michael, MD, Bekaii-Saab, Tanios, MD

Volltext

Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia von KLISOVIC, Rebecca B, BLUM, William, ZWIEBEL, James A, DEVINE, Steven, BYRD, John C, GREVER, Michael R, CHAN, Kenneth, MARCUCCI, Guido, XIAOHUI WEI, SHUJUN LIU, ZHONGFA LIU, ZHILIANG XIE, VUKOSAVLJEVIC, Tamara, KEFAUVER, Cheryl, HUYNH, Lenguyen, JIUXIA PANG

Volltext

Simultaneous bilateral total knee arthroplasties: Who decides? von LOMBARDI, Adolph V, MALLORY, Thomas H, FADA, Robert A, HARTMAN, Jodi F, CAPPS, Susan G, KEFAUVER, Cheryl A, DODDS, Kathleen, ADAMS, Joanne B

Volltext

An algorithm for the posterior cruciate ligament in total knee arthroplasty von LOMBARDI, Adolph V, MALLORY, Thomas H, FADA, Robert A, HARTMAN, Jodi F, CAPPS, Susan G, KEFAUVER, Cheryl A, ADAMS, Joanne B

Volltext

Phase II randomized double blind trial of axitinib (Axi) +/- PF-04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC... von Sadeghi, Sarmad, Parikh, Rahul Atul, Tsao-Wei, Denice D., Groshen, Susan G., Li, Ming, Appleman, Leonard Joseph, Tagawa, Scott T., Nanus, David M., Molina, Ana M., Kefauver, Cheryl, Ornstein, Moshe Chaim, Rini, Brian I., Dreicer, Robert, Quinn, David I., Lara, Primo "Lucky" N.

Volltext

Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653) von Sadeghi, Sarmad, Groshen, Susan G, Tsao-Wei, Denice D, Parikh, Rahul, Mortazavi, Amir, Dorff, Tanya B, Kefauver, Cheryl, Hoimes, Christopher, Doyle, Laurence, Quinn, David I, Newman, Edward, Lara, Jr, Primo N

Volltext

Noncemented acetabular component removal in the presence of osteolysis: The affirmative von MALLORY, Thomas H, LOMBARDI, Adolph V, FADA, Robert A, ADAMS, Joanne B, KEFAUVER, Cheryl A, EBERLE, Robert W

Volltext

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13 von Fehniger, Todd A., Byrd, John C., Marcucci, Guido, Abboud, Camille N., Kefauver, Cheryl, Payton, Jacqueline E., Vij, Ravi, Blum, William

Volltext

A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma von Varker, Kimberly A, Biber, Jennifer E, Kefauver, Cheryl, Jensen, Rhonda, Lehman, Amy, Young, Donn, Wu, Haifeng, Lesinski, Gregory B, Kendra, Kari, Chen, Helen X, Walker, Michael J, Carson, 3rd, William E

Volltext

A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia von Maddocks, Kami, Ruppert, Amy S, Browning, Rebekah, Jones, Jeffrey, Flynn, Joseph, Kefauver, Cheryl, Gao, Yue, Jiang, Yao, Rozewski, Darlene M, Poi, Ming, Phelps, Mitch A, Harper, Erica, Johnson, Amy J, Byrd, John C, Andritsos, Leslie A

Volltext

Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine von Blum, William, Klisovic, Rebecca B, Walker, Alison, Schwind, Sebastian, Jiang, Yao, Wang, Jiang, Phelps, Mitch, Geyer, Susan, Devine, Steven M., Walsh, Kathy, Vasu, Sumithira, Curfman, John P., Schaaf, Larry, Garr, Celia, Kefauver, Cheryl, Byrd, John C., Grever, Michael R., Garzon, Ramiro, Marcucci, Guido

Volltext

In Reply von Andritsos, Leslie A., Lin, Thomas S., Blum, William, Kefauver, Cheryl, Johnson, Amy J., Byrd, John C.

Volltext